American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
REDWOOD CITY, Calif., Feb. 18, 2016 -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Tuesday, March 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 638-4817 for domestic callers or (262) 912-6051 for international callers and referencing Conference ID: 38718399. To listen to a live webcast, please visit the investor relations section of Avinger's website at: www.avinger.com.
A replay of the call will be available beginning March 1, 2016 at 4:30pm PT/7:30pm ET through midnight on March 2, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 38718399. The webcast will also be available on Avinger's website for one year following the completion of the call.
About Avinger, Inc.
Avinger, Inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral arterial disease (PAD). PAD is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. The Company’s mission is to dramatically improve the treatment of vascular disease through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. Avinger’s current lumivascular products include the Lightbox™ imaging console, the Ocelot™ family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or CTOs, and Pantheris™, the first-ever image-guided atherectomy device, designed to precisely remove arterial plaque in PAD patients. For more information, please visit the Company's website at www.avinger.com.
"Avinger," “Pantheris” and the Avinger logo are registered trademarks of Avinger, Inc.
Investor Contact: Westwicke Partners Leigh Salvo (415) 513-1281 Email: [email protected]
